EUCTR2007-003290-29-EE进行中（未招募）不适用
A phase II, observer-blind, multicountry, multicentre, randomized study to demonstrate the non-Inferiority of GlaxoSmithKline Biologicals’ one-container AS25 adjuvanted influenza vaccine compared to GlaxoSmithKline Biologicals’ two-container AS25 adjuvanted influenza vaccine in adults aged 65 years and above. - FluAS25-020 PRI
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,560
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, reporting by phone) should be enrolled in the study.
- •A male or female aged 65 years or older at the time of the vaccination.
- •Written informed consent obtained from the subject.
- •Free of an acute aggravation of the health status as established by clinical evaluation (medical history and medical history directed examination) before entering into the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period.
- •Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to Visit 2 after vaccination.
- •Planned administration of an influenza vaccine other than the study vaccines during the entire study period.
- •Vaccination against influenza since January 2007 (including the Northern Hemisphere NH 2006/2007 or NH 2007/08 influenza vaccine).
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine. (For corticosteroids, this will mean prednisone, or equivalent, >0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •History of hypersensivity to a previous dose of influenza vaccine.
- •History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) including egg, chicken protein, formaldehyde, gentamicin sulphate, thiomersal or sodium deoxycholate and adjuvant AS25 (containing squalene, alpha-tocopherol, Tween 80 and MPL).
- •Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation (medical history and medical history directed physical examination) or pre-existing laboratory screening tests.
- •Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature <37.5°C).
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study.
- •Any medical conditions in which IM injections are contraindicated.
研究者
相似试验
进行中（未招募）
不适用
A phase II, observer-blind, multicountry, multicentre, randomized study to demonstrate the non-Inferiority of GlaxoSmithKline Biologicals’ one-container AS25 adjuvanted influenza vaccine compared to GlaxoSmithKline Biologicals’ two-container AS25 adjuvanted influenza vaccine in adults aged 65 years and above. - FluAS25-020 PRIEUCTR2007-003290-29-DKGlaxoSmithKline Biologicals1,560
进行中（未招募）
不适用
A phase II, observer-blind, multicountry, multicentre, randomized study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals’ influenza vaccine adjuvanted with various doses of the oil in water emulsion and MPL, administered in adults aged 65 years and older, and compared to Fluarix™. - FluAS25-025 PRIEUCTR2007-003802-86-DEGlaxoSmithKline Biologicals2,000
进行中（未招募）
不适用
A phase II, observer-blind, multicountry, multicentre, randomized study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals’ influenza vaccine adjuvanted with various doses of the oil in water emulsion and MPL, administered in adults aged 65 years and older, and compared to Fluarix™. - FluAS25-025 PRIEUCTR2007-003802-86-SEGlaxoSmithKline Biologicals2,000
进行中（未招募）
不适用
A phase II, observer-blind, multicountry, multicentre, randomized study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals’ influenza vaccine adjuvanted with various doses of the oil in water emulsion and MPL, administered in adults aged 65 years and older, and compared to Fluarix™. - FluAS25-025 PRIImmunization against influenza in male and female subjects aged 18-40 years old and 65 years and above.EUCTR2007-003802-86-GBGlaxoSmithKline Biologicals2,000
进行中（未招募）
1 期
A phase II, observer-blind, multicountry, multicentre, randomized study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals’ influenza vaccine adjuvanted with various doses of the oil in water emulsion and MPL, administered in adults aged 65 years and older, and compared to Fluarix™. - FluAS25-025 PRIEUCTR2007-003802-86-NLGlaxoSmithKline Biologicals2,000